Academia.eduAcademia.edu

Figure 3 – uploaded by Sung-Hun Lee

See full PDFdownloadDownload figure
Abbreviations: AUC, area under the curve; IHC, immunohistochemical; ROC, receiver operating characteristic; SD, standard deviation Table 3. Results of receiver operating characteristic (ROC) curve analysis of EMT/MET markers, transcription factors, and histone modification enzymes determining the cutoff value on the lung adenocarcinoma and the brain metastasis.

Table 3 Abbreviations: AUC, area under the curve; IHC, immunohistochemical; ROC, receiver operating characteristic; SD, standard deviation Table 3. Results of receiver operating characteristic (ROC) curve analysis of EMT/MET markers, transcription factors, and histone modification enzymes determining the cutoff value on the lung adenocarcinoma and the brain metastasis.

Related Figures (11)

Abbreviations: CI, confidence interval; KPS, Karnofsky performance scale. Table 1. Clinical features of entire cohorts with brain metastasis of lung adenocarcinoma at the time of diaonnciec af metactacia tn the hrain (y — AB)
Abbreviations: CI, confidence interval; KPS, Karnofsky performance scale. Table 1. Clinical features of entire cohorts with brain metastasis of lung adenocarcinoma at the time of diaonnciec af metactacia tn the hrain (y — AB)
Abbreviation: EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to-epithelial transition. Table 2. Immunohistochemical staining of EMT/MET markers, transcription factors, and histone modification enzymes on the lung adenocarcinoma and brain metastasis in the paired samples (n = 46). Table 2. Immunohistochemical staining of EMT/MET markers, transcription factors, and histone
Abbreviation: EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to-epithelial transition. Table 2. Immunohistochemical staining of EMT/MET markers, transcription factors, and histone modification enzymes on the lung adenocarcinoma and brain metastasis in the paired samples (n = 46). Table 2. Immunohistochemical staining of EMT/MET markers, transcription factors, and histone
Brain Metastasis
Brain Metastasis
Brain Metastasis
Brain Metastasis
increased expression of UTX in the immunohistochemical analysis simultaneously (cutoff value of 70%). A significant linear correlation between the expression of ZEB1 and UTX was also observed in direct proportion (R? linear = 1.204) (Figure 4B). This result indicates that UTX, as an H3K27me3 demethylase, could epigenetically induce the expression of ZEB1. In contrast, 18 samples (78.3%) showed increased expression of Twist in the immunohistochemical analysis (cutoff value of 45%), and of these samples, 17 samples (94.4%) showed decreased expression of EZH2 in the immunohistochemica analysis (cutoff value of 10%). A significant linear correlation between the expression of Twist and EZH2 was also observed in reverse proportion (R2 linear = —2.723) (Figure 4C). This result indicates that EZH2, as an H3K27 methyltransferase, could epigenetically suppress the expression of Twist. However, these epigenetic relationships were not observed in lung adenocarcinoma samples; R? linear of 0.273 between Slug and MLL4, R2 linear of 0.351 between ZEB1 and UTX, and R? linear of —0.184 between Twist and EZH2. In addition, no additional statistical correlation was found between other EMT-TFs and histone lysine modifying enzymes in lung adenocarcinoma and BM samples. Figure 4. The illustration of epigenetic regulation on the expression between epithelial-to-mesenchymal transition transcription factor and histone lysine modification enzymes in the brain metastasis. (A,D) MLL4 as H3K4 methyltransferase induces the expression of Slug, (B,E) UTX as H3K27me3 demethylase induces the expression of ZEB1, and (C,F) EZH2 as H3H27 demethylase reduces the expression of Twist.
increased expression of UTX in the immunohistochemical analysis simultaneously (cutoff value of 70%). A significant linear correlation between the expression of ZEB1 and UTX was also observed in direct proportion (R? linear = 1.204) (Figure 4B). This result indicates that UTX, as an H3K27me3 demethylase, could epigenetically induce the expression of ZEB1. In contrast, 18 samples (78.3%) showed increased expression of Twist in the immunohistochemical analysis (cutoff value of 45%), and of these samples, 17 samples (94.4%) showed decreased expression of EZH2 in the immunohistochemica analysis (cutoff value of 10%). A significant linear correlation between the expression of Twist and EZH2 was also observed in reverse proportion (R2 linear = —2.723) (Figure 4C). This result indicates that EZH2, as an H3K27 methyltransferase, could epigenetically suppress the expression of Twist. However, these epigenetic relationships were not observed in lung adenocarcinoma samples; R? linear of 0.273 between Slug and MLL4, R2 linear of 0.351 between ZEB1 and UTX, and R? linear of —0.184 between Twist and EZH2. In addition, no additional statistical correlation was found between other EMT-TFs and histone lysine modifying enzymes in lung adenocarcinoma and BM samples. Figure 4. The illustration of epigenetic regulation on the expression between epithelial-to-mesenchymal transition transcription factor and histone lysine modification enzymes in the brain metastasis. (A,D) MLL4 as H3K4 methyltransferase induces the expression of Slug, (B,E) UTX as H3K27me3 demethylase induces the expression of ZEB1, and (C,F) EZH2 as H3H27 demethylase reduces the expression of Twist.
Abbreviations: CI, confidence interval; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to -epithelial transition. Table 4. Univariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers and transcription factors on the lung adenocarcinoma.
Abbreviations: CI, confidence interval; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to -epithelial transition. Table 4. Univariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers and transcription factors on the lung adenocarcinoma.
Abbreviation. CI, confidence interval; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to -epithelial transition. Table 5. Univariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers and transcription factors on the brain metastasis.
Abbreviation. CI, confidence interval; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to -epithelial transition. Table 5. Univariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers and transcription factors on the brain metastasis.
Abbreviations: BM, brain metastasis; CI, confidence interval; EMT, epithelial-to-mesenchymal transition; KPS, Karnofsky performance scale; MET, mesenchymal-to-epithelial transition. Table 6. Multivariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers, transcription factors, and histone modification enzymes on the lung adenocarcinoma and the brain metastasis.
Abbreviations: BM, brain metastasis; CI, confidence interval; EMT, epithelial-to-mesenchymal transition; KPS, Karnofsky performance scale; MET, mesenchymal-to-epithelial transition. Table 6. Multivariate analysis of factors predicting longer survival according to the immunoreactivity of the EMT/MET markers, transcription factors, and histone modification enzymes on the lung adenocarcinoma and the brain metastasis.
580 California St., Suite 400
San Francisco, CA, 94104
© 2025 Academia. All rights reserved